{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:31:39Z","timestamp":1788273099511,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100008323","name":"Cumberland Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,12,20]]},"abstract":"<jats:p>\n            Adults with cystic fibrosis (CF) frequently harbor\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            , which is increasingly antibiotic resistant. Telavancin is a once-daily rapidly bactericidal antibiotic active against methicillin-, linezolid-, and ceftaroline-resistant\n            <jats:named-content content-type=\"genus-species\">S. aureus<\/jats:named-content>\n            . Because CF patients experience alterations in pharmacokinetics, the optimal dose of telavancin in this population is unknown.\n          <\/jats:p>","DOI":"10.1128\/aac.01914-19","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T13:50:22Z","timestamp":1572616222000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation"],"prefix":"10.1128","volume":"64","author":[{"given":"James M.","family":"Kidd","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Harford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Sakon","sequence":"additional","affiliation":[{"name":"Indiana University Health, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Marie","family":"Oleksiuk","sequence":"additional","affiliation":[{"name":"UPMC Presbyterian Shadyside Hospital, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Cies","sequence":"additional","affiliation":[{"name":"St. Christopher\u2019s Hospital for Children, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Pettit","sequence":"additional","affiliation":[{"name":"Riley Hospital for Children, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Harford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Harford, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Cystic Fibrosis Foundation. 2017. Patient registry annual data report. Cystic Fibrosis Foundation Bethesda MD. https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2017-Patient-Registry-Annual-Data-Report.pdf. Accessed 4 September 2019."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23217"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.12.003"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.10.014"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23132"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1681"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01392-13"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02067-15"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001171"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.34.4.550"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00773-15"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn273"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00875-07"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-07"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008634911114"},{"key":"e_1_3_3_17_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. Performance standards for antimicrobial susceptibility testing, 29th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"29"},{"key":"e_1_3_3_18_2","volume-title":"Quantitative evaluation of telavancin exposure-response relationships among patients in the assessment of telavancin for treatment of hospital-acquired pneumonia (ATTAIN) trials, abstr AAID LB20","author":"Patel N","year":"2019","unstructured":"Patel N, Lo A, Barriere S, Lodise T. 2019. Quantitative evaluation of telavancin exposure-response relationships among patients in the assessment of telavancin for treatment of hospital-acquired pneumonia (ATTAIN) trials, abstr AAID LB20. Abstr ASM Microbe 2019, New Orleans, LA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.195-201.2005"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05915-11"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00383-11"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1847-6"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.8.806"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02475-17"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.08.003"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835040-00004"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0678-x"},{"key":"e_1_3_3_28_2","volume-title":"Vibativ (telavancin) prescribing information","author":"Cumberland Pharmaceuticals","year":"2018","unstructured":"Cumberland Pharmaceuticals. 2018. Vibativ (telavancin) prescribing information. Cumberland Pharmaceuticals, Nashville, TN."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00956-18"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31825c4ba6"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00281-17"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01914-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01914-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:43:09Z","timestamp":1645479789000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01914-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,20]]}},"alternative-id":["10.1128\/AAC.01914-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.01914-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]},"assertion":[{"value":"2019-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01914-19"}}